Edgewise Therapeutics (EWTX) Other Non-Current Assets (2020 - 2025)

Edgewise Therapeutics has disclosed Other Non-Current Assets across 6 years of filings, most recently posting $695000.0 for Q1 2025.

• Other Non-Current Assets for Q1 2025 came in at $695000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2025 was $695000.0 (changed N/A YoY), and the FY2024 annual result was $262000.0, down 24.71% from the prior year.
• Other Non-Current Assets came in at $695000.0 for Q1 2025 at Edgewise Therapeutics, up from $262000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $695000.0 in Q1 2025 to a low of $201000.0 in Q1 2021.
• The 5-year median for Other Non-Current Assets is $295000.0 (2021), against an average of $368733.3.
• Across the five-year window, Other Non-Current Assets surged 178.11% in 2022 and sank 55.1% in 2023, its largest moves.
• Edgewise Therapeutics' Other Non-Current Assets stood at $548000.0 in 2021, then plunged by 54.2% to $251000.0 in 2022, then soared by 38.65% to $348000.0 in 2023, then retreated by 24.71% to $262000.0 in 2024, then surged by 165.27% to $695000.0 in 2025.
• The last three Other Non-Current Assets figures came in at $695000.0 (Q1 2025), $262000.0 (Q4 2024), and $262000.0 (Q3 2024), per Business Quant data.